These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36161830)

  • 61. Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema.
    Yigit K; Inan ÜÜ; Inan S; Dogan M; Yavas GF; Cetinkaya E
    Int Ophthalmol; 2021 Apr; 41(4):1487-1501. PubMed ID: 33486648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema.
    Srinivas S; Verma A; Nittala MG; Alagorie AR; Nassisi M; Gasperini J; Sadda SR
    Am J Ophthalmol; 2020 Mar; 211():183-190. PubMed ID: 31758926
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Factors predicting the treatment frequency of ranibizumab injections during the second year in diabetic macular edema.
    Nishikawa K; Murakami T; Ishihara K; Dodo Y; Terada N; Morino K; Tsujikawa A
    Jpn J Ophthalmol; 2022 May; 66(3):296-304. PubMed ID: 35438397
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.
    Chaudhary V; Sarohia GS; Phillips MR; Park D; Xie J; Zeraatkar D; Fung M; Thabane L; Loewenstein A; Holz FG; Garg SJ; Kaiser PK; Bhandari M; Guymer RH; Fraser-Bell S; Sivaprasad S; Wykoff CC
    Eye (Lond); 2023 Jul; 37(10):1966-1974. PubMed ID: 36369263
    [TBL] [Abstract][Full Text] [Related]  

  • 68. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
    Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
    Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Associations and Prognostic Significance of Fluctuations in Diabetic Retinopathy Severity in Eyes Treated for Diabetic Macular Edema.
    Cicinelli MV; Gregori G; Rabiolo A; Tombolini B; Barresi C; Pignatelli F; Lattanzio R; Bandello F
    Ophthalmologica; 2023; 246(2):131-140. PubMed ID: 36996777
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
    Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
    Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS.
    Staurenghi G; Lai TYY; Mitchell P; Wolf S; Wenzel A; Li J; Bhaumik A; Hykin PG;
    Ophthalmology; 2018 Jun; 125(6):850-862. PubMed ID: 29371007
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
    Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
    Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.
    Hoerauf H; Feltgen N; Weiss C; Paulus EM; Schmitz-Valckenberg S; Pielen A; Puri P; Berk H; Eter N; Wiedemann P; Lang GE; Rehak M; Wolf A; Bertelmann T; Hattenbach LO;
    Am J Ophthalmol; 2016 Sep; 169():258-267. PubMed ID: 27163237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.